Search

Danaher Corp

Gesloten

SectorGezondheidszorg

191.98 -0.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

189.24

Max

193.94

Belangrijke statistieken

By Trading Economics

Inkomsten

-168M

1B

Verkoop

-887M

6B

K/W

Sectorgemiddelde

39.511

62.58

EPS

2.06

Dividendrendement

0.67

Winstmarge

17.291

Werknemers

58,000

EBITDA

-560M

1.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.17% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

0.67%

2.19%

Volgende Winsten

20 okt 2026

Volgende dividenddatum

31 jul 2026

Volgende Ex Dividend datum

25 sep 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4B

142B

Vorige openingsprijs

192.08

Vorige sluitingsprijs

191.98

Nieuwssentiment

By Acuity

47%

53%

151 / 340 Rangschikking in Healthcare

Danaher Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 jul 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 jul 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 jul 2026, 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 jul 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Peer Vergelijking

Prijswijziging

Danaher Corp Prognose

Koersdoel

By TipRanks

14.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 219.78 USD  14.17%

Hoogste 240 USD

Laagste 195 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Danaher Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

17

Buy

3

Hold

0

Sell

Sentiment

By Acuity

151 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat